Imprime PGG-mediated anti-cancer immune activation requires immune complex formation

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Chan, Anissa S H ^a   Jonas, Adria Bykowski ^a   Qiu, Xiaohong ^a   Ottoson, Nadine R ^a   Walsh, Richard M ^a   Gorden, Keith B ^a   Harrison, Ben ^a   Maimonis, Peter J ^a   Leonardo, Steven M ^a   Ertelt, Kathleen E ^a   Danielson, Michael E ^a   Michel, Kyle S ^a   Nelson, Mariana ^a   Graff, Jeremy R ^a   Patchen, Myra L ^a   Bose, Nandita ^a  

^a Biothera   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA GLUCAN; BETA GLUCAN ANTIBODY; CHEMOKINE; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; FC RECEPTOR IIA; IMPRIME; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC AGENT; CD11B ANTIGEN; FC RECEPTOR;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL PHAGOCYTOSIS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; HUMAN; HUMAN CELL; INNATE IMMUNITY; MONOCYTE; NEUTROPHIL; NORMAL HUMAN; PHENOTYPE; TUMOR CELL; CHEMISTRY; DRUG EFFECTS; HEK293 CELL LINE; IMMUNOLOGY; METABOLISM;

ANTIGEN-ANTIBODY COMPLEX; ANTINEOPLASTIC AGENTS; BETA-GLUCANS; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; MACROPHAGE-1 ANTIGEN; RECEPTORS, IGG;

EID: 84994314253     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0165909     Document Type: Article

References (56)

1. Zent CS, Call TG, Bowen DA, Conte MJ, LaPlant BR, Witzig TE, et al. Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. Leukemia & lymphoma. 2015; 56(8):2373-8. doi:10.3109/10428194.2015.1016932 PMID: 25676035; PubMed Central PMCID: PMCPMC4573786.
2. Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 2008; 113(8):2110-8. doi:10.1002/cncr.23824 PMID: 18759253; PubMed Central PMCID: PMC2849723.
3. Li B, Allendorf DJ, Hansen R, Marroquin J, Cramer DE, Harris CL, et al. Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer research. 2007; 67(15):7421-30. doi:10.1158/00085472.CAN-07-1465 PMID: 17671212; PubMed Central PMCID: PMC1933500.
4. Li B, Allendorf DJ, Hansen R, Marroquin J, Ding C, Cramer DE, et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol. 2006; 177(3):1661-9. PMID: 16849475.
5. Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, et al. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans. Blood. 2011; 117(25):6825-36. doi:10.1182/blood-2011-02-339812 PMID: 21531981; PubMed Central PMCID: PMC3128477.
6. Salvador C, Li B, Hansen R, Cramer DE, Kong M, Yan J. Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(4):1239-47. doi:10.1158/1078-0432.CCR-07-1669 PMID: 18281559; PubMed Central PMCID: PMC2394864.
7. Zhong W, Hansen R, Li B, Cai Y, Salvador C, Moore GD, et al. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models. Journal of immunotherapy. 2009; 32(7):703-12. doi:10.1097/CJI. 0b013e3181ad3fcf PMID: 19561538.
8. Bose N, Wurst LR, Chan AS, Dudney CM, LeRoux ML, Danielson ME, et al. Differential regulation of oxidative burst by distinct beta-glucan-binding receptors and signaling pathways in human peripheral blood mononuclear cells. Glycobiology. 2014; 24(4):379-91. doi:10.1093/glycob/cwu005 PMID: 24440830.
9. Bose N, Chan AS, Guerrero F, Maristany CM, Qiu X, Walsh RM, et al. Binding of Soluble Yeast beta-Glucan to Human Neutrophils and Monocytes is Complement-Dependent. Frontiers in immunology. 2013; 4:230. doi:10.3389/fimmu.2013.00230 PMID: 23964276; PubMed Central PMCID: PMC3740326.
10. Milton DK, Alwis KU, Fisette L, Muilenberg M. Enzyme-linked immunosorbent assay specific for (1→6) branched, (1→3)-beta-D-glucan detection in environmental samples. Appl Environ Microbiol. 2001; 67(12):5420-4. doi:10.1128/AEM.67.12.5420-5424.2001 PMID: 11722887; PubMed Central PMCID: PMCPMC93324.
11. Masuzawa S, Yoshida M, Ishibashi K, Saito N, Akashi M, Yoshikawa N, et al. Solubilized candida cell Wall β-glucan, CSBG, is an epitope of natural human antibody. Drug development research. 2003; 58 (2):179-89. Epub Mar 27, 2003. doi:10.1002/ddr.10158
12. Chiani P, Bromuro C, Cassone A, Torosantucci A. Anti-beta-glucan antibodies in healthy human subjects. Vaccine. 2009; 27(4):513-9. doi:10.1016/j.vaccine.2008.11.030 PMID: 19041357.
13. Ishibashi K, Morita M, Motoi M, Liu Y, Miura NN, Adachi Y, et al. Analysis of the Titer and Reactivity of Antibody/ies Against Fungal Cell Wall beta-Glucans in Human Sera. International journal of medicinal mushrooms. 2013; 15(2):115-26. Epub 2013/04/06. PMID: 23557364.
14. Barrett DJ, Ayoub EM. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clinical and experimental immunology. 1986; 63(1):127-34. PMID: 3955880; PubMed Central PMCID: PMC1577346.
15. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009; 113(16):3716-25. doi:10.1182/blood-2008-09-179754 PMID: 19018092.
16. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. The Journal of clinical investigation. 2005; 115 (10):2914-23. doi:10.1172/JCI24772 PMID: 16167082; PubMed Central PMCID: PMC1201664.
17. Parren PW, Warmerdam PA, Boeije LC, Arts J, Westerdaal NA, Vlug A, et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. The Journal of clinical investigation. 1992; 90(4):1537-46. doi:10.1172/JCI116022 PMID: 1401085; PubMed Central PMCID: PMC443201.
18. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. 1991; 147(4):1338-43. PMID: 1831223.
19. Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. The Journal of clinical investigation. 1992; 89(4):1274-81. doi:10.1172/JCI115712 PMID: 1532589; PubMed Central PMCID: PMC442988.
20. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nature reviews Immunology. 2013; 13(3):176-89. doi:10.1038/nri3401 PMID: 23411799.
21. Segal NH, Gada P, Senzer N, Gargano MA, Patchen ML, Saltz LB. A phase 2 efficacy and safety, open-label, multicenter study of Imprime PGG injection in combination with cetuximab in patients with stage IV KRAS-mutant colorectal cancer. Journal of Clinical Coloretal Cancer. 2016; In press. Epub February 13, 2016. http://dx.doi.org/10.1016/j.clcc.2016.02.013.
22. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol. 2007; 25(5):555-61. doi:10.1038/nbt1303 PMID: 17483842.
23. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(22):9422-7. doi:10.1073/pnas.0703498104 PMID: 17517625; PubMed Central PMCID: PMCPMC1868655.
24. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al. Crossreacting antibodies enhance dengue virus infection in humans. Science. 2010; 328(5979):745-8. doi:10.1126/science.1185181 PMID: 20448183; PubMed Central PMCID: PMCPMC3837288.
25. Taylor A, Foo SS, Bruzzone R, Dinh LV, King NJ, Mahalingam S. Fc receptors in antibody-dependent enhancement of viral infections. Immunological reviews. 2015; 268(1):340-64. doi:10.1111/imr.12367 PMID: 26497532.
26. Walport MJ Complement. First of two parts. The New England journal of medicine. 2001; 344 (14):1058-66. doi:10.1056/NEJM200104053441406 PMID: 11287977.
27. Lucisano Valim YM, Lachmann PJ. The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clinical and experimental immunology. 1991; 84(1):1-8. PMID: 1707767; PubMed Central PMCID: PMC1535367.
28. Hao J, Meng LQ, Xu PC, Chen M, Zhao MH. p38MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation. PloS one. 2012; 7(5):e38317. doi:10.1371/journal.pone.0038317 PMID: 22675451; PubMed Central PMCID: PMC3365028.
29. Schaeffer V, Cuschieri J, Garcia I, Knoll M, Billgren J, Jelacic S, et al. The priming effect of C5a on monocytes is predominantly mediated by the p38 MAPK pathway. Shock. 2007; 27(6):623-30. doi:10.1097/SHK.0b013e31802fa0bd PMID: 17505301.
30. Daniels RH, Finnen MJ, Hill ME, Lackie JM. Recombinant human monocyte IL-8 primes NADPH-oxidaseand phospholipase A2 activation in human neutrophils. Immunology. 1992; 75(1):157-63. PMID: 1537592; PubMed Central PMCID: PMC1384818.
31. Leoratti FM, Trevelin SC, Cunha FQ, Rocha BC, Costa PA, Gravina HD, et al. Neutrophil paralysis in Plasmodium vivax malaria. PLoS neglected tropical diseases. 2012; 6(6):e1710. doi:10.1371/journal. pntd.0001710 PMID: 22745844; PubMed Central PMCID: PMC3383745.
32. Schwarzer E, Alessio M, Ulliers D, Arese P. Phagocytosis of the malarial pigment, hemozoin, impairs expression of major histocompatibility complex class II antigen, CD54, and CD11c in human monocytes. Infect Immun. 1998; 66(4):1601-6. PMID: 9529087; PubMed Central PMCID: PMC108094.
33. Fortunati E, Kazemier KM, Grutters JC, Koenderman L, Van den Bosch v J. Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease. Clinical and experimental immunology. 2009; 155(3):559-66. doi:10.1111/j.1365-2249.2008.03791.x PMID: 19077082; PubMed Central PMCID: PMC2669533.
34. Rigby KM, DeLeo FR. Neutrophils in innate host defense against Staphylococcus aureus infections. Seminars in immunopathology. 2012; 34(2):237-59. doi:10.1007/s00281-011-0295-3 PMID: 22080185; PubMed Central PMCID: PMC3271231.
35. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2009; 29(6):313-26. doi:10.1089/jir.2008.0027 PMID: 19441883; PubMed Central PMCID: PMC2755091.
36. Ghosh TK, Mickelson DJ, Fink J, Solberg JC, Inglefield JR, Hook D, et al. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cellular immunology. 2006; 243(1):48-57. doi:10.1016/j.cellimm.2006.12.002 PMID: 17250816.
37. Hood JD, Warshakoon HJ, Kimbrell MR, Shukla NM, Malladi SS, Wang X, et al. Immunoprofiling tolllike receptor ligands: Comparison of immunostimulatory and proinflammatory profiles in ex vivo human blood models. Hum Vaccin. 2010; 6(4):322-35. PMID: 20372068.
38. Halstenson CE, Shamp T, Gargano MA, Walsh RM, Patchen ML. Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3-1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects. Investigational new drugs. 2016. Epub 2016 Feb 11. doi: 10.1007/s10637-016-0325-z PMID: 26865390
39. Perkins H, Khodai T, Mechiche H, Colman P, Burden F, Laxton C, et al. Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model. Journal of clinical immunology. 2012; 32(5):1082-92. doi:10.1007/s10875-012-9687-y PMID: 22476912.
40. Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer immunology, immunotherapy: CII. 2010; 59(12):1877-84. doi:10.1007/s00262-010-0914-1 PMID: 20820775; PubMed Central PMCID: PMC4098785.
41. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nature reviews Immunology. 2008; 8(1):34-47. doi:10.1038/nri2206 PMID: 18064051.
42. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. Nature reviews Immunology. 2014; 14(2):94-108. doi:10.1038/nri3582 PMID: 24445665.
43. Huang ZY, Hunter S, Chien P, Kim MK, Han-Kim TH, Indik ZK, et al. Interaction of two phagocytic host defense systems: Fcgamma receptors and complement receptor 3. The Journal of biological chemistry. 2011; 286(1):160-8. Epub 2010/11/04. doi:10.1074/jbc.M110.163030 PMID: 21044955; PubMed Central PMCID: PMC3012970.
44. Petty HR, Todd RF 3rd. Receptor-receptor interactions of complement receptor type 3 in neutrophil membranes. Journal of leukocyte biology. 1993; 54(5):492-4. PMID: 8228627.
45. Zhou MJ, Brown EJ. CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation. The Journal of cell biology. 1994; 125(6):1407-16. PMID: 7515890; PubMed Central PMCID: PMC2290913.
46. Cheson BD, Morris SE. The role of complement and IgG on zymosan opsonization. International archives of allergy and applied immunology. 1981; 66(1):48-54. PMID: 7263086.
47. Sipka S, Abel G, Csongor J, Chihara G, Fachet J. Effect of lentinan on the chemiluminescence produced by human neutrophils and the murine macrophage cell line C4M phi. International journal of immunopharmacology. 1985; 7(5):747-51. PMID: 4044098.
48. Brandsma AM, Jacobino SR, Meyer S, ten Broeke T, Leusen JH. Fc receptor inside-out signaling and possible impact on antibody therapy. Immunological reviews. 2015; 268(1):74-87. doi:10.1111/imr.12332 PMID: 26497514.
49. Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, et al. Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'. Nature. 2011; 472(7344):471-5. doi:10.1038/nature10071 PMID: 21525931; PubMed Central PMCID: PMCPMC3084546.
50. Wang L, Han G, Wang R, Chen G, Xu R, Xiao H, et al. Regulation of IL-8 production by complement activated product, C5a, in vitro and in vivo during sepsis. Clin Immunol. 2010; 137(1):157-65. doi:10.1016/j.clim.2010.05.012 PMID: 20591742.
51. Ember JA, Sanderson SD, Hugli TE, Morgan EL. Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin. Am J Pathol. 1994; 144(2):393-403. PMID: 7508686; PubMed Central PMCID: PMCPMC1887151.
52. Hunniger K, Bieber K, Martin R, Lehnert T, Figge MT, Loffler J, et al. A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a. J Immunol. 2015; 194(3):1199-210. doi:10.4049/jimmunol.1401845 PMID: 25539819.
53. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood. 2002; 100(5):1869-77. Epub 2002/08/15. PMID: 12176911.
54. Fukuoka Y, Medof EM. C5a receptor-mediated production of IL-8 by the human retinal pigment epithelial cell line, ARPE-19. Curr Eye Res. 2001; 23(5):320-5. PMID: 11910520.
55. Tsuboi N, Ernandez T, Li X, Nishi H, Cullere X, Mekala D, et al. Regulation of human neutrophil Fcgamma receptor IIa by C5a receptor promotes inflammatory arthritis in mice. Arthritis and rheumatism. 2011; 63(2):467-78. doi:10.1002/art.30141 PMID: 21280001; PubMed Central PMCID: PMCPMC3128197.
56. Ravetch JV A full complement of receptors in immune complex diseases. The Journal of clinical investigation. 2002; 110(12):1759-61. doi:10.1172/JCI17349 PMID: 12488423; PubMed Central PMCID: PMCPMC151658.